A multi-centre feasibility study to understand the benefits of a new intervention designed to reduce muscle overactivity in people with knee osteoarthritis

BEhaviour change to reduce Pain in Knee Osteoarthritis (BEPKO-2) - a feasibility study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25291958

Enrollment

Registered

2022-04-27

Start date

2022-05-16

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis Musculoskeletal Diseases Arthrosis

Interventions

Researchers have developed a new physiotherapy treatment that may help people who do not experience benefit from muscle-strengthening physiotherapy. This new treatment teaches patients how they can st

Eligibility

Sex/Gender

All

Age

40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Above 40 years old 2. Speak and understand English sufficient to read the information sheet and sign the consent form 3. Ability to walk without an assistive device for at least 100 m (to ensure patients have sufficient mobility to be able to complete the intervention) 4. Clinical diagnosis of KOA according to American College of Rheumatology (ACR) criteria 5. Pain for at least 6 months' duration 6. Attended a minimum of six (of 10/12) ESCAPE pain classes 7. Improvement in KOOS following ESCAPE <15% from their pre-ESCAPE condition

Exclusion criteria

Exclusion criteria: 1. Dementia or other major cognitive impairment 2. BMI >33 kg/m² (as increased subcutaneous fat prevents the collection of surface EMG signals) 3. Lower limb arthroplasty 4. Any systemic inflammatory disorders, such as rheumatoid arthritis 5. Any balance disorders which may increase the risk of a fall 6. Not fully vaccinated against COVID-19 (for the safety of the physiotherapist and research staff)

Design outcomes

Primary

Measure	Time frame
Pain and function measured using the WOMAC questionnaire at baseline, 20 weeks and 8 months	—

Secondary

Measure	Time frame
1. Pain catastrophisation measured using the Pain catastrophizing scale at baseline, 20 weeks and 8 months 2. Kinesiophobia measured using the Tampa scale of kinesiophobia at baseline, 20 weeks and 8 months 3. Anxiety and depression measured using the Generalised Anxiety and Depression Scale at baseline, 20 weeks and 8 months 4. Health-related quality of life measured using the EQ-5D-5L at baseline, 20 weeks and 8 months 5. Health resource utilisation measured using a custom questionnaire at baseline, 20 weeks and 8 months 6. Work productivity and activity impairment measured using the work productivity and activity impairment (WPAI) questionnaire at baseline, 20 weeks and 8 months	—

Measure

Time frame

1. Pain catastrophisation measured using the Pain catastrophizing scale at baseline, 20 weeks and 8 months 2. Kinesiophobia measured using the Tampa scale of kinesiophobia at baseline, 20 weeks and 8 months 3. Anxiety and depression measured using the Generalised Anxiety and Depression Scale at baseline, 20 weeks and 8 months 4. Health-related quality of life measured using the EQ-5D-5L at baseline, 20 weeks and 8 months 5. Health resource utilisation measured using a custom questionnaire at baseline, 20 weeks and 8 months 6. Work productivity and activity impairment measured using the work productivity and activity impairment (WPAI) questionnaire at baseline, 20 weeks and 8 months

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026